ES2579835T3 - Formulación de anticuerpo - Google Patents

Formulación de anticuerpo Download PDF

Info

Publication number
ES2579835T3
ES2579835T3 ES09764858.8T ES09764858T ES2579835T3 ES 2579835 T3 ES2579835 T3 ES 2579835T3 ES 09764858 T ES09764858 T ES 09764858T ES 2579835 T3 ES2579835 T3 ES 2579835T3
Authority
ES
Spain
Prior art keywords
months
dpx
sec
sum
acz885
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09764858.8T
Other languages
English (en)
Spanish (es)
Inventor
Joachim Momm
Hans-Joachim Wallny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2579835(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2579835T3 publication Critical patent/ES2579835T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES09764858.8T 2008-12-10 2009-12-09 Formulación de anticuerpo Active ES2579835T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
EP08170884 2008-12-10
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation

Publications (1)

Publication Number Publication Date
ES2579835T3 true ES2579835T3 (es) 2016-08-17

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09764858.8T Active ES2579835T3 (es) 2008-12-10 2009-12-09 Formulación de anticuerpo
ES16162699T Active ES2900624T3 (es) 2008-12-10 2009-12-09 Formulación de anticuerpos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16162699T Active ES2900624T3 (es) 2008-12-10 2009-12-09 Formulación de anticuerpos

Country Status (30)

Country Link
US (3) US20110236398A1 (enExample)
EP (6) EP2196476A1 (enExample)
JP (6) JP6143416B2 (enExample)
KR (2) KR20170044211A (enExample)
CN (3) CN102245639B (enExample)
AU (1) AU2009324371B2 (enExample)
CA (1) CA2745938C (enExample)
CL (1) CL2011001406A1 (enExample)
CO (1) CO6361952A2 (enExample)
CY (2) CY1117735T1 (enExample)
DK (2) DK3072906T3 (enExample)
EC (1) ECSP11011192A (enExample)
ES (2) ES2579835T3 (enExample)
HR (2) HRP20160754T1 (enExample)
HU (2) HUE028408T2 (enExample)
IL (3) IL264316B2 (enExample)
LT (1) LT3072906T (enExample)
MA (1) MA33023B1 (enExample)
MX (1) MX2011006242A (enExample)
MY (2) MY157772A (enExample)
NZ (1) NZ592918A (enExample)
PE (1) PE20120342A1 (enExample)
PL (2) PL3072906T3 (enExample)
PT (2) PT2376533T (enExample)
RU (2) RU2563179C2 (enExample)
SI (2) SI3072906T1 (enExample)
SM (1) SMT201600222B (enExample)
TN (1) TN2011000229A1 (enExample)
WO (1) WO2010066762A1 (enExample)
ZA (1) ZA201103362B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013123114A2 (en) * 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9801362B2 (en) * 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
UY35460A (es) * 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
SMT202100317T1 (it) * 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
EP3487584A1 (en) * 2016-07-21 2019-05-29 Novartis AG Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
BR112019005328A2 (pt) * 2016-09-27 2019-06-18 Fresenius Kabi Deutschland Gmbh composição farmacêutica líquida
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
WO2018234879A1 (en) * 2017-06-22 2018-12-27 Novartis Ag USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
RU2020113234A (ru) * 2017-09-13 2021-10-13 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА
BR112020019065A2 (pt) * 2018-03-23 2020-12-29 AbbVie Deutschland GmbH & Co. KG Formulações de anticorpo anti-tau aquosas estáveis
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CA2963828A1 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
CA2681743A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
EP2376533B1 (en) 2016-03-30
LT3072906T (lt) 2021-12-27
KR101762966B1 (ko) 2017-07-31
TN2011000229A1 (en) 2012-12-17
CN104399076A (zh) 2015-03-11
MX2011006242A (es) 2011-06-24
JP2026021446A (ja) 2026-02-10
DK2376533T3 (en) 2016-06-27
AU2009324371A1 (en) 2011-06-23
HK1159130A1 (zh) 2012-07-27
KR20170044211A (ko) 2017-04-24
EP4789682A2 (en) 2026-08-12
CY1124844T1 (el) 2022-11-25
CN102245639B (zh) 2014-12-24
CL2011001406A1 (es) 2012-03-30
JP7286595B2 (ja) 2023-06-05
AU2009324371B2 (en) 2013-10-10
SMT201600222B (it) 2016-08-31
CA2745938A1 (en) 2010-06-17
HRP20211899T1 (hr) 2022-03-04
US20110236398A1 (en) 2011-09-29
KR20120009421A (ko) 2012-01-31
RU2011127913A (ru) 2013-01-20
DK3072906T3 (da) 2021-12-13
RU2015132431A3 (enExample) 2018-12-24
CO6361952A2 (es) 2012-01-20
HUE056626T2 (hu) 2022-02-28
US8623367B2 (en) 2014-01-07
EP2376533A1 (en) 2011-10-19
SI2376533T1 (sl) 2016-07-29
HUE028408T2 (en) 2016-12-28
PT2376533T (pt) 2016-07-13
IL264316B1 (en) 2023-09-01
US20120315285A1 (en) 2012-12-13
JP6143416B2 (ja) 2017-06-07
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
CA2745938C (en) 2018-04-24
PL2376533T3 (pl) 2016-09-30
EP3792282A1 (en) 2021-03-17
MY166050A (en) 2018-05-22
ZA201103362B (en) 2012-01-25
WO2010066762A1 (en) 2010-06-17
RU2015132431A (ru) 2018-12-24
IL212922A0 (en) 2011-07-31
CN104399076B (zh) 2021-09-14
EP2196476A1 (en) 2010-06-16
IL264316B2 (en) 2024-01-01
PE20120342A1 (es) 2012-04-24
IL212922B (en) 2019-02-28
JP2023109938A (ja) 2023-08-08
CN114225022A (zh) 2022-03-25
US20200384108A1 (en) 2020-12-10
ECSP11011192A (es) 2011-08-31
EP3072906A1 (en) 2016-09-28
PT3072906T (pt) 2021-12-14
CN102245639A (zh) 2011-11-16
SI3072906T1 (sl) 2022-01-31
JP2015231997A (ja) 2015-12-24
JP2020203889A (ja) 2020-12-24
EP4792831A2 (en) 2026-08-19
ES2900624T3 (es) 2022-03-17
EP3072906B1 (en) 2021-09-08
RU2563179C2 (ru) 2015-09-20
IL264316A (en) 2019-02-28
IL276622A (en) 2020-09-30
HRP20160754T1 (hr) 2016-08-12
PL3072906T3 (pl) 2022-01-24
RU2745601C2 (ru) 2021-03-29
BRPI0922730A2 (en) 2018-11-06
JP2012511540A (ja) 2012-05-24
JP2018168158A (ja) 2018-11-01
CY1117735T1 (el) 2017-05-17
MA33023B1 (fr) 2012-02-01

Similar Documents

Publication Publication Date Title
US20190023743A1 (en) Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
TWI332845B (en) Aqueous sustained-release formulations of proteins
Hanwright et al. Sustained IGF-1 delivery ameliorates effects of chronic denervation and improves functional recovery after peripheral nerve injury and repair
RU2745601C2 (ru) Составы, содержащие антитела
ES2153385T5 (es) Composicion acuosa a base de hormona del crecimiento humana.
TWI233361B (en) Methods of preventing UVB-induced skin damage
ES2950570T3 (es) Composición farmacéutica del complejo de proteína il-15 y usos de la misma
UA99830C2 (uk) Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок
KR20170086049A (ko) 증가된 소수성을 가지는 단백질과 단백질 콘쥬게이트
Liang et al. Screening natural cholesterol analogs to assemble self‐adjuvant lipid nanoparticles for antigens tagging guided therapeutic tumor vaccine
CN114423447A (zh) 用于延释组合物的疏水性肽盐
ES2287980T3 (es) Composicion farmaceutica placebo liofilizable destinada a imitar un medicamento, en particular a base de proteinas o e polipeptidos.
ES2992499T3 (es) Composición para acelerar la proliferación celular que comprende péptido derivado de eritropoyetina
ES2452015T3 (es) Composiciones que incluyen diferentes tipos de factores de transferencia, métodos para elaborar las composiciones, y métodos de tratamiento usando las composiciones
RU2549986C2 (ru) Модифицированный эритропоэтин, к которому присоединена водорастворимая длинноцепочечная молекула
CN102670522A (zh) 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备
Ahmed et al. Expression of Ki67 in submandibular salivary glands of rabbits after BTX injection: Histological and immunohistochemical study
CN102648978B (zh) 一种稳定的蛋白药物制剂及其制备方法
US20210145941A1 (en) Pharmaceutical compositions for treating acid sphingomyelinase deficiency
ES2912162T3 (es) Composiciones de insulina de acción rápida
US20230174580A1 (en) Molecular transport system to the central nervous system
CN115581766A (zh) 一种结合PD-L1/TGFβ双功能抗体融合蛋白液体制剂
US20060178311A1 (en) Control of lactation
Neuhofer Development of lipid based depot formulations using interferon-beta-1b as a model protein
Ramesh et al. Approved Protein Therapeutics and Their Biochemical Targets